Personalizing Locoregional Therapy for Patients with Metastatic Colorectal Cancer
- 104 Downloads
Purpose of review
The management of metastatic colorectal liver disease has improved overall survival by multidisciplinary approach utilizing systemic treatment followed by local control of metastatic disease. There has been an evolution of local control therapy which has expanded the new armamentarium for treatment of resectable and unresectable liver disease. The review article will address the various types of locoregional therapy and various indications for its use.
The application of ablative therapies combined with resections has allowed single-stage resection for patients with bilobar disease with excellent safety and efficacy. In patients with unresectable colorectal metastasis to the liver, chemo- and radio-embolization have provided improved survival outcome compared to systemic chemotherapy alone.
Locoregional therapy for metastatic colorectal liver disease can improve outcome as an adjunctive role in combination with resection or as a sole therapy for patients with unresectable disease.
KeywordsMetastatic colorectal cancer Locoregional therapy Ablation Irreversible electroporation Radioembolization Chemoembolization
Compliance with Ethical Standards
Conflict of Interest
Young Hong and Robert C.G. Martin II declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.•• Xu W et al. Survival benefit and safety of the combinations of FOLFOXIRI +/− bevacizumab versus the combinations of FOLFIRI +/− bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis. Onco Targets Ther. 2016;9:4833–42. Improved combination chemotherapy regimen can improve overall and progression free survival with acceptable toxicity and should be used in patients with metastatic colorectal cancer.PubMedPubMedCentralCrossRefGoogle Scholar
- 7.Pietrantonio F, et al. Perioperative triplet chemotherapy and cetuximab in patients with RAS wild type high recurrence risk or borderline resectable colorectal cancer liver metastases. Clin Color Cancer. 2016.Google Scholar
- 14.• Fagard K et al. The impact of frailty on postoperative outcomes in individuals aged 65 and over undergoing elective surgery for colorectal cancer: a systematic review. J Geriatr Oncol. 2016;7(6):479–91. Frailty of the patient should be addressed as a potential impact on outcome in patients with resectable metastatic disease.PubMedCrossRefGoogle Scholar
- 23.National Comprehensive Cancer Network. Colon Cancer (Version 2.2016). February 4, 2017; Available from: http://www.nccn.org/professionals/physician_gls/pfd/coloncancer.pdf.
- 31.Philips P, et al. Safety and advantages of combined resection and microwave ablation in patients with bilobar hepatic malignancies. Int J Hyperth. 2016;1–21.Google Scholar
- 35.•• Gani F et al. Patterns of hepatic resections in North America: use of concurrent partial resections and ablations. HPB (Oxford). 2016;18(10):813–20. Combined partial wedge resection and ablative therapy had equivalent outcome as those with partial lobectomy in patients with metastatic colorectal cancer to the liver.CrossRefGoogle Scholar
- 44.•• North DA et al. Microwave ablation for hepatic malignancies: a call for standard reporting and outcomes. Am J Surg. 2014;208(2):284–94. There are wide variation in reporting of outcomes after microwave ablation which prevents accurate comparison of studies that are published. Consistent terminology will help communicate effectively across various centers that perform ablative therapy.PubMedCrossRefGoogle Scholar
- 52.Ruers T, Punt C, Coevorden F, Pierie JP, Rinkes I, Ledermann J, Poston G, Bechstein W, Lentz MA, Mauer M, Cutsem E, Lutz M, Nordlinger B. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). In 2015 ASCO Annual Meeting. 2015.Google Scholar
- 62.Martin RC, O.C.R. Microwave ablation and irreversible electroporation, in Blumgart’s surgery of the liver, pancreas and biliary tract, W.R. Jarnagin, Editor. 2016. Elsevier Health Sciences.Google Scholar
- 67.•• Correa-Gallego C et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol. 2014;21(13):4278–83. Comparision of microwave ablation versus radiofrequency ablation demonstrated a decreased local recurrence.Google Scholar
- 69.Francone E, et al. Precoagulation-assisted parenchyma-sparing laparoscopic liver surgery: rationale and surgical technique. Surg Endosc. 2016.Google Scholar
- 70.•• Groeschl RT et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg. 2014;259(6):1195–200. Local recurrence of a lesion after microwave ablation was correlated with size of the tumor. Tumor greater than 3cm was associated with increased risk of local recurrence after microwave ablation.PubMedCrossRefGoogle Scholar
- 77.•• Bhutiani N et al. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB (Oxford). 2016;18(7):593–9. Irreversible electroporation can be utilized in patients with hepatocellular carcinoma as an additional non-thermal treatment option.CrossRefGoogle Scholar
- 78.Bond L, et al. Intra-operative navigation of a 3-dimensional needle localization system for precision of irreversible electroporation needles in locally advanced pancreatic cancer. Eur J Surg Oncol. 2016.Google Scholar
- 82.Dhir M, et al. Robotic-assisted placement of an hepatic artery infusion pump and catheter for regional chemotherapy of the liver. Ann Surg Oncol. 2016.Google Scholar
- 100.•• Jones RP, et al. PARAGON II—a single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. Eur J Surg Oncol. 2016. Single DEBIRI infusion had similar safety and efficacy as traditional systemic chemotherapy for resectable metastatic colorectal disease of the liver.Google Scholar
- 103.•• Martin RC et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649–58. Combination of systemic chemotherapy FOLFOX plus bevacizumab and DEBIRI demonstrated improved overall and progression free survival in patients with unresectable metastatic colorectable liver disease.PubMedCrossRefGoogle Scholar
- 113.van Hazel GA et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723–31.PubMedCrossRefGoogle Scholar
- 114.Dutton SJ et al. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional selective internal radiation therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer. 2014;14:497.PubMedPubMedCentralCrossRefGoogle Scholar